Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER

BACKGROUND: Thromboprophylaxis extended after hospital discharge in medically ill patients currently is not recommended by practice guidelines because of uncertainty about the benefit for preventing major or fatal thromboembolic events, and the risk of bleeding. METHODS AND RESULTS: We assessed the...

Descripción completa

Detalles Bibliográficos
Autores principales: Raskob, Gary E., Spyropoulos, Alex C., Spiro, Theodore E., Lu, Wentao, Yuan, Zhong, Levitan, Bennett, Suh, Eunyoung, Barnathan, Elliot S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751917/
https://www.ncbi.nlm.nih.gov/pubmed/34755519
http://dx.doi.org/10.1161/JAHA.121.021579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751917/
https://www.ncbi.nlm.nih.gov/pubmed/34755519
http://dx.doi.org/10.1161/JAHA.121.021579

Ejemplares similares